Key result
Family screening for ATTRv according to the 2021 ESC recommendations demonstrated a 97% negative predictive value, with only 3% of relatives without screening indications diagnosed with ATTRv-CM.
Why the study?
Does family screening according to the 2021 ESC recommendations improve early diagnosis of ATTRv-CM in relatives of probands with ATTRv?
Does family screening according to the 2021 ESC recommendations improve early diagnosis of ATTRv-CM in relatives of probands with ATTRv?
Answers are grounded in this paper and cite their sources.
This editorial highlights that the 2021 ESC recommendations for family screening in ATTRv have a high negative predictive value, while emphasizing the extreme phenotypic variability and the need for structured multidisciplinary management.
This article refers to ‘Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis’ by S.A. Muller et al., published in this issue on pages 2025–2034. Cardiac amyloidosis (CA) is strongly gaining the main scene in the clinical arena of cardiologists worldwide. The epidemiology revolution of CA started with the non-invasive diagnostic work-up proposed for the first time in 2016, with the perfect combo of diphosphonate scintigraphy and monoclonal protein investigation, allowing cardiologists to find CA in common syndromes and disease, including heart failure (12% and 10% in heart failure with preserved and reduced ejection fraction, respectively), hypertrophic cardiomyopathy/unexplained left ventricular hypertrophy (7%), aortic stenosis (8%), atrioventricular blocks (2%).1 In 2021, a position paper of the European Society of Cardiology (ESC) Working Group on Myocardial and Pericardial Diseases detailed the clinical pathway of CA, prompting the role of cardiologists in all the disease stages, proposing ‘red flags’ for raising suspicion of CA and a diagnostic algorithm to allow appropriate diagnosis in patients with suggestive clinical presentation, highlighting the importance of an aetiological diagnosis of CA (wild-type transthyretin amyloidosis [ATTRwt]; variant transthyretin amyloidosis [ATTRv]; light-chain [AL] amyloidosis) to access a specific treatment, advising on the importance of follow-up in patients with CA and in family members of probands with ATTRv.2 The 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2023 ESC guidelines for the management of cardiomyopathies (CMPs) reinforced the concept of phenotyping heart failure and CMPs to obtain an aetiology-based treatment (targeted therapies) of phenocopies, including CA.3, 4 The ‘CMP mindset’ and the principle of ‘red flags’ are the universally accepted approaches in CMPs.5 In the CMP guidelines, it is also clearly stated that clinical work-up requires a rigorously structured CMP unit, with multi-imaging, genetic and pathology facilities, and with a multidisciplinary team including neurologists, haematologists, nephrologists, and other specialty physicians to facilitate diagnosis and management of different phenocopies. Variant transthyretin amyloidosis is a perfect paradigm of the complexity of phenocopies, and of the importance to work in a well organized setting.2, 4 It is a very heterogeneous disease, where neurologists historically played a major role. ATTRv is an autosomal dominant disorder with incomplete penetrance: some pathogenic variants in TTR are preferentially associated with a neurological phenotype, others with cardiological phenotype, the most expressing a mixed phenotype with neurological and cardiological involvement. It is now a treatable disease, and a timely and definite diagnosis is essential in view of the availability of effective therapies in probands and family members. The clinical presentation is various, influenced by several features, including age of onset, ethnicity, genotype and penetrance of mutation, and disease duration. When ‘red flags’ support a strong suspicion of CA, and AL or ATTRwt is unlikely, it is mandatory for cardiologists to suspect ATTRv and ask for genetic testing (CMP next generation sequencing gene panel or focused TTR gene investigation). Indeed, in the cardiology setting, with the growing interest in CA, and the new clinical realities dedicated to CMPs/heart failure and CA, the number of patients diagnosed with CA other than the most common ATTRwt is increasing. This has important advantages, including early diagnosis of AL and ATTRv in a different setting than haematology and neurology; on the other hand, it also potentially represents a burden, particularly managing family members at risk of developing the disease. Thus, defining effective protocols for screening individuals carrying TTR pathogenic variants is urgent due to the availability of new pharmacological treatments that can potentially modify the natural history of the disease in its early stage, and to avoid a significant burden on the CA dedicated clinics. In this issue of the Journal, Muller et al.6 assessed the recommendations for family screening in ATTRv suggested by the 2021 ESC position statement on the diagnosis and treatment of cardiac amyloidosis. The ESC suggests starting screening for ATTRv carriers at the first sign of extra-cardiac manifestations or, for those without extra-cardiac manifestations, 10 years before the family's youngest member developed the phenotype or at the typical age for the specific variant (40 years for Val50Met and 55 years for non-Val50Met). The study evaluated disease penetrance at baseline, the value of serial assessments, and the accuracy and yield of first-level diagnostic tests (electrocardiogram [ECG], echocardiogram and biomarkers) to validate these recommendations based predominantly on expert consensus. According to the results of a recent investigation, showing that grade I cardiac uptake in bone scintigraphy in absence of monoclonal proteins has a 98% likelihood of being transthyretin amyloidosis cardiomyopathy (ATTR-CM),7 in contrast to the ESC position statement, the authors considered ATTRv-CM diagnosis in presence of grade I cardiac tracer uptake in bone scintigraphy. The study included 159 individuals from 104 families, mostly (82%) asymptomatic and primarily identified through cascade genetic screening. A quarter (25%) of the population was diagnosed with ATTRv-CM, with half exhibiting cardiac manifestations (mainly heart failure), and the other half showing subclinical disease. Relatives with ATTRv at baseline were more often male, sibling of the proband and more likely to have ‘red flags’, neurologic symptoms, cardiac involvement (heart failure and pacemaker-requiring conduction disorders). The main results of the study were: (i) a high negative predictive value (97%) of the indication for screening according to the ESC position papers, as a diagnosis of ATTRv-CM in relatives without an indication for screening was rare (3%; n = 2/66); (ii) relatives who fulfil criteria for early screening are only diagnosed with subclinical ATTRv-CM; (iii) male sex and infrequently identified (rare) variants are independent predictors for ATTRv-CM; consequently, the absence of infrequently identified variants and female sex in relatives with an indication for screening yielded a good negative predictive value (84%) for screening; (iv) overall, 7/41 (17%) relatives developed ATTRv-CM, with a median time to ATTRv-CM diagnosis of 3.4 [2.5–5.6] years; when utilizing the proposed 3-year screening interval by bone scintigraphy of the 2021 ESC position statement to intercept subjects progressing to clinical disease, the diagnostic yield was 9.4%; (v) 26% (n = 5/19) of relatives with subclinical ATTRv-CM did not show any ‘red flags’ of ATTRv-CM on first-line diagnostic tests and 29% (n = 2/7) of relatives progressing towards ATTRv-CM showed no ‘red flags’ on first-line diagnostic tests; (vi) on the other hand, 33% of relatives without ATTRv-CM showed ‘red flags’ of ATTRv-CM on first-line diagnostic tests with a prevalence comparable to the general population, and attributed to alternative causes (e.g. coronary artery disease); and (vii) the relevance of a closer follow-up (2 years) with Holter monitoring in relatives with conduction disorders, even with negative bone scintigraphy. This is the first study investigating the 2021 ESC proposal for family screening in relatives at risk for developing ATTRv-CM. The results of the study highlight the extreme variability of the phenotype according to age, ethnicity, genotype, and the importance of knowing the disease ‘red flags’ with their clinical penetrance, sensitivity and specificity at different disease stages. An expert physician, dealing with CA, is required to know the extreme variability of disease expression linked to different genotypes, and take the right clinical decision accordingly: (i) screening should be initiated earlier (40 and 55 years of age) in subjects carrying the frequent Val50Met variant compared with subjects carrying non-Val50Met variants (disease onset >65 years of age); nevertheless, the physician should be aware that the penetrance may vary in endemic and non- endemic areas; (ii) patients with specific TTR mutations (Ile68Leu, Phe84Leu, Ser97Tyr) have negative bone scintigraphy (false negative), and cardiac magnetic resonance can be mandatory in these patients and relatives to suspect the diagnosis; (iii) the ‘African variant’ Val122Ile (probably underestimated in the Caucasian and worldwide population) is associated with a predominant cardiac phenotype, raising the risk of progressive disease and heart failure in carriers; and (iv) male patients with rare TTR variants are more likely to develop clinical disease, compared to females without rare TTR variants. However, limitations other that reported by the authors (retrospective nature, referral and centre bias, treatment efficacy in patients with early phenotype and/or no ‘red flags’) need to be acknowledged. In particular, the timing of bone scintigraphy (3 years), cardiac magnetic resonance imaging (3 years), and Holter ECG (2 years), similar to what suggested for other CMPs, needs confirmation in larger studies. The feasibility in all centres at a national/international level and cost-effectiveness of the protocol should be further investigated. In conclusion, the multifaceted clinical presentation of ATTRv represents a challenge in everyday practice even for expert clinicians, required to suspect, diagnose and treat the disease, but also to investigate clinical and subclinical presentation in family members at risk for developing ATTRv. This necessitates a profound knowledge of the genotype–phenotype expression and its great variability, the awareness of current guidelines and work-up to follow, and a structured multidisciplinary setting. As in the Pirandello novel ‘One, no one and one hundred thousand’, the different faces of the disease in the real-world setting should be recomposed, and the pieces of a complex puzzle put in the right place, at the right time, with the aim of unveiling early presentation in probands and family members. Conflict of interest: none declared.
No takes yet. Share an insight, caveat, or question.
Limongelli et al. (2024) conducted an editorial in Hereditary transthyretin cardiac amyloidosis (ATTRv) (n=159). 2021 ESC recommendations for family screening was evaluated on Diagnosis of ATTRv-CM. Family screening for ATTRv according to the 2021 ESC recommendations demonstrated a 97% negative predictive value, with only 3% of relatives without screening indications diagnosed with ATTRv-CM.
Synapse has enriched 10 related papers. Consider them for comparative context: